#USA #New York #Pomerantz Law Firm #Agio #Agios Pharmaceuticals

Pomerantz Law Firm Investigates Agios Pharmaceuticals

The Pomerantz Law Firm has initiated an investigation into potential claims on behalf of investors in Agios Pharmaceuticals, Inc., a company listed under NASDAQ with the symbol AGIO. This action comes in response to concerns regarding possible securities fraud and unlawful business practices carried out by Agios and some of its key officers and directors.

On September 4, 2025, Agios made public an announcement regarding the U.S. Food and Drug Administration’s (FDA) decision to delay the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of its drug PYRUKYND® (mitapivat). This delay pushed the review timeline back by three months, ultimately rescheduling the new target date to December 7, 2025.

Following the news regarding the FDA's delay, the market responded swiftly. Agios’s stock price plummeted by $4.48, reflecting a decline of approximately 11.03%, leading the share price to close at $36.13 on the same day. Such steep drops raise significant questions about the company's communication and the impact of the delayed review on investor interests.

In view of these developments, the Pomerantz Law Firm, which has a long-standing reputation for handling corporate and securities litigation, is urging investors affected by this situation to reach out. Danielle Peyton, a representative from the firm, can be contacted via email or through their office phone number, which is provided above for interested parties.

The Pomerantz Firm has been at the forefront of securities class actions for over 80 years, having been founded by the esteemed attorney Abraham L. Pomerantz. Known in legal circles as the dean of the class action bar, Pomerantz’s legacy includes advocating for victims of securities fraud and corporate wrongdoing, helping recover substantial damages for investors over the years.

The firm currently boasts a widespread presence with offices located in key financial hubs, including New York, Chicago, Los Angeles, London, and Paris. They have built a reputation for their vigorous advocacy on behalf of affected investors and stakeholders in various corporate settings.

As the investigation unfolds, affected investors are encouraged to stay informed about any developments. Legal proceedings in cases like this can lead to significant financial recoveries for class members. Moreover, investors can join the class action suit by following the necessary procedures as outlined by the law firm. Those interested in taking action should promptly consider their options, as time-sensitive matters like this can be integral for the pursuit of justice and compensation.

Conclusion

In summary, the current investigation into Agios Pharmaceuticals by the Pomerantz Law Firm highlights significant issues impacting the company and its investors. The recent FDA review delay has instigated a critical examination of potential securities violations, prompting affected shareholders to seek legal recourse. As always, investors should remain vigilant and consult with legal experts to navigate this complicated landscape effectively.